In postmenopausal women , yearly intravenous zoledronate ( ZOL ) compared to placebo ( PLB ) significantly increased bone mineral density ( BMD ) at lumbar spine ( LS ) , femoral neck ( FN ) , and total hip ( TH ) and decreased fracture risk .